Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.celrep.2013.02.001 | DOI Listing |
Publication Analysis
Top Keywords
renal cell
4
cell cancer
4
cancer treated
4
treated single-edged
4
single-edged sword
4
sword preclinical
4
preclinical early
4
early clinical
4
clinical data
4
data antiangiogenic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!